Barclays lowered Solid Biosciences' price target while other firms upgraded their ratings.

Barclays lowered Solid Biosciences' price target from $18.00 to $15.00, while other firms like Leerink Partners, Piper Sandler, SVB Leerink, HC Wainwright, and JPMorgan Chase & Co upgraded their ratings and targets for the life science company. Solid Biosciences focuses on developing therapies for neuromuscular and cardiac diseases, with lead product candidates SGT-003 and SGT-501. The company has a market cap of $342.38m and a beta of 1.84.